Stryker Q2 net income jumps 44.3% to $1.28B on 9.4% revenue growth

Filed July 31, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 1, 2025 · ~1 min read

Key Changes

• high

  Net income rose 44.3% to $1.28B, with diluted EPS up 44.1% to $3.30, driven by a 260 bps tariff reversal and lower acquisition costs.

  MD&A: Operating margin verify on EDGAR →
• high

  Operating margin expanded to 25.2% from 18.5%, aided by a one-time reversal of 2025 tariffs and lower inventory step-up amortization.

  MD&A: Operating margin verify on EDGAR →
• high

  Completed acquisition of AVS for $435M cash plus up to $400M in milestones, adding a next-gen intravascular lithotripsy platform.

  Notes: Acquisition of AVS verify on EDGAR →